ASCO 2010- Abstracts from the yearly meeting of the American Society of Clinical Oncology

  June 11, 2010- German CML Study IV: randomized, treatment optimization trial......

http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202010/

Tracks/Hematologic%20Malignancies/Capsules/6517.aspx

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year

Read more here: http://abstract.asco.org/AbstView_74_51091.html

Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)

Abstract: read more here: http://abstract.asco.org/AbstView_74_52917.html

Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.

Abstract: read more here: http://abstract.asco.org/AbstView_74_52814.html

Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib

Abstract: read more here: http://abstract.asco.org/AbstView_74_53560.html

Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.

Abstract: read more here:     http://asco.org/AbstView_74_53232.html